Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
21 | DE file number | DAKZ | 60 2013 077 422.6 |
96 | EP file number | EAKZ | 19 16 9275.5 |
97 | EP publication number | EPN | 3533792 |
54 | Designation/title | TI | KRISTALLINE FORMEN EINES ANDROGENREZEPTORMODULATORS |
51 | IPC main class | ICM (ICMV) | C07D 401/04 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | A61K 31/4439 (2006.01), A61K 31/4184 (2006.01), A61P 35/00 (2006.01) |
22 | DE application date | DAT | Jun 4, 2013 |
96 | EP application date | EAT | Jun 4, 2013 |
43 | Date of first publication | OT | Sep 4, 2019 |
| Date of publication of grant | PET | May 5, 2021 |
71/73 | Applicant/owner | INH | Aragon Pharmaceuticals, Inc., Los Angeles, CA, US; Sloan Kettering Institute For Cancer Research, New York, NY, US |
72 | Inventor | IN | DILHAS, Anna, 4055 Basel, CH; OUERFELLI, Ouathek, Fort Lee, NJ 07024, US; SMITH, Nicholas D., San Diego, CA 92109, US; HERBERT, Mark R., San Diego, CA 92111, US |
74 | Representative | VTR | Müller-Boré & Partner Patentanwälte PartG mbB, 80639 München, DE |
| Address for service | | Müller-Boré & Partner Patentanwälte PartG mbB, 80639 München, DE |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 201261656888 P Jun 7, 2012
|
| Due date | FT FG | Jun 30, 2025 Annual fee for the 13th year
Patent fees |
| Patent division in charge | | 44 |
21 | File number of protection certificate | ZAKZ | 12 2021 000 067.4 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000003533792A1 Searchable text:
EP000003533792A1 Original document:
EP000003533792B1 Searchable text:
EP000003533792B1 |
43 | Date of first publication | EVT | Sep 4, 2019 |
| Date of the first transfer into DPMAregister | EREGT | Sep 4, 2019 |
| Date of the (most recent) update in DPMAregister | REGT | Sep 19, 2024 (Show all update days)(Hide all update days)- Sep 19, 2024
- Procedures: Opposition procedure, Decision by EPO to maintain patent in full has become final, 14.05.2024: changed
- Aug 15, 2024
- Procedures: Opposition procedure, Patent maintained in full by EPO, 14.05.2024: new
- Procedures: Opposition procedure, Decision by EPO to maintain patent in full has become final, 14.05.2024: new
- May 14, 2024; May 10, 2023; May 14, 2022; Mar 31, 2022; Feb 24, 2022; Nov 18, 2021; May 18, 2021; May 5, 2021; Apr 15, 2021
- Historical data not available for this/these date(s)
- Sep 4, 2019
- Date of the first transfer into DPMAregister
|